跳至主要内容
临床试验/NCT07516977
NCT07516977尚未招募不适用

A Clinical Study to Evaluate the Effectiveness of Combined Use of Two Nasal Protective Medical Devices (Noseguard and Noseguard Night) for Reducing Respiratory Infection Rates and Assessing Usability

Daewoong Pharmaceutical Co. LTD.1 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2026年4月20日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
2,000
试验地点
1
主要终点
Incidence of Respiratory Infection

研究概览

简要总结

This study is a prospective clinical study to evaluate the effectiveness of combined use of two nasal protective medical devices (Noseguard and Noseguard Night) in reducing respiratory infection rates, including COVID-19 and influenza, in real-world conditions.

The study will also assess usability, satisfaction, and safety using electronic patient-reported outcomes (ePRO).

详细描述

This study is a prospective clinical study conducted in Korea to evaluate the effectiveness of combined use of two nasal protective medical devices, Noseguard and Noseguard Night, for preventing respiratory infections.

A total of approximately 2,000 adult participants will be enrolled and followed for 8 weeks. Participants will use Noseguard during daytime activities and Noseguard Night before sleep.

Data will be collected using electronic patient-reported outcomes (ePRO) at baseline and at Weeks 2, 4, 6, and 8. The primary endpoint is the incidence of respiratory infections, including COVID-19 and influenza.

Secondary endpoints include symptom severity, duration of symptoms, usability, satisfaction, and safety outcomes such as adverse events.

This study aims to generate real-world evidence on the effectiveness and usability of nasal protective devices for respiratory infection prevention.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults aged ≥19 years
  • Able to provide informed consent

排除标准

  • Hypersensitivity to device components
  • Current COVID-19 or influenza infection
  • Severe nasal disease
  • Pregnant or breastfeeding women

研究组 & 干预措施

Noseguard Combined Use

Experimental

Participants will use Noseguard during daytime activities and Noseguard Night before sleep for 8 weeks.

干预措施: Noseguard and Noseguard Night (Device)

结局指标

主要结局

Incidence of Respiratory Infection

时间窗: Week 8

Incidence of respiratory infections, including COVID-19 and influenza, during the 8-week study period.

次要结局

  • Incidence of Respiratory Infection by Interval(Up to Week 8)

研究者

发起方
Daewoong Pharmaceutical Co. LTD.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验